First worldwide multicenter validation of the POLARIS preclinical polarizer across biological models and imaging paradigms

Abstract Hyperpolarized ¹³C Magnetic Resonance Imaging (HP-MRI) enables real-time, non-invasive assessment of metabolism in diseases including cancer and neurodegeneration. Broader adoption has been limited by the complexity, duration, and lack of standardization of current hyperpolarization methods. This study evaluated POLARIS Preclinical, a parahydrogen-induced polarization (PHIP) hyperpolarizer designed to streamline production of hyperpolarized ¹³C agents. Four POLARIS systems were deployed across eight international research centers to produce hyperpolarized [1-¹³C]pyruvate doses within 90 seconds. In vitro and in vivo imaging was conducted in multiple animal models using MRI systems operating at 1.4, 3, 7, and 9.4 Tesla. Metabolic conversion of pyruvate to lactate and bicarbonate was successfully measured across all sites. POLARIS enabled rapid, reproducible production of hyperpolarized [1-¹³C]pyruvate and demonstrated consistent performance across instruments, institutions, and field strengths. These results support standardized, high-throughput metabolic MRI for multicenter studies and translational research in oncology, neurology, and cardiovascular disease.